HCW Biologics clings on with $5M lifeline to fund phase 1 alopecia trial
Despite securing a much-needed $5 million lifeline from an equity offering this week, HCW Biologics is continuing to warn that its financial future remains in doubt.
Despite securing a much-needed $5 million lifeline from an equity offering this week, HCW Biologics is continuing to warn that its financial future remains in doubt.
